- NLS Pharmaceutics ( NASDAQ: NLSP ) said the Japanese Patent Office is granting a patent for the proprietary formulation of Quilience (Mazindol ER).
- The company said the patent — application 2018-546837 —will cover oral formulations containing immediate-release and sustained-release layers of mazindol and their use in treating attention deficit disorder/hyperactivity disorder (ADHD), excessive daytime sleepiness including narcolepsy and idiopathic hypersomnia (IH).
- "Given our patent estate and the Orphan Drug Designations that we have in both the U.S. and Europe, we believe that our proprietary position on Quilience is strong. We look forward to reporting the final results from our Phase 2a narcolepsy trial for Quilience in late September 2022 and also providing an update from the open-label extension study later this year," said NLS CEO Alex Zwyer.
For further details see:
NLS Pharma to get Japanese patent related to Quilience for attention, sleep disorders